• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Vital Signs: Hepatitis C Treatment Among Insured Adults - United States, 2019-2020
CONCLUSIONS AND IMPLICATIONS FOR PUBLIC HEALTH PRACTICE: Few insured persons with diagnosed hepatitis C receive timely DAA treatment, and disparities in treatment exist. Unrestricted access to timely DAA treatment is critical to reducing viral hepatitis-related mortality, disparities, and transmission. Treatment saves lives, prevents transmission, and is cost saving.PMID:35951484 | DOI:10.15585/mmwr.mm7132e1
Source: MMWR Morb Mortal Wkl... - August 11, 2022 Category: Epidemiology Authors: William W Thompson Hasan Symum Amy Sandul DHSc Neil Gupta Priti Patel Noele Nelson Jonathan Mermin Carolyn Wester Source Type: research

Cost-effectiveness of total state coverage for hepatitis C medications
CONCLUSIONS: Medicare-Medicaid partnerships to pay for all HCV treatments today represent good value and a low budget impact. States with trouble covering HCV treatments should consider using this model to plan coverage decisions.PMID:34002969 | DOI:10.37765/ajmc.2021.88640
Source: The American Journal of Managed Care - May 18, 2021 Category: Health Management Authors: William V Padula Jonathan S Levin Joy Lee Gerard F Anderson Source Type: research

Access to direct-acting antivirals for hepatitis C-negative transplant recipients receiving organs from hepatitis C-viremic donors
CONCLUSION: In this study, all HCV-negative recipients who developed HCV following transplantation had access to DAA therapy, with the majority starting treatment in the first month after transplantation.PMID:33987658 | DOI:10.1093/ajhp/zxab207
Source: American Journal of Health-System Pharmacy : AJHP - May 14, 2021 Category: Drugs & Pharmacology Authors: Sarah Bova Andrew Cameron Christine Durand Jennifer Katzianer Meighan LeGrand Lauren Boyer Jaime Glorioso Lindsey P Toman Source Type: research

Drug Prices And Medical Innovation: A Response To Yu, Helms, and Bach
In a recent Health Affairs Blog post, Nancy Yu, Zachary Helms, and Peter Bach note that prices for top-selling drugs are higher in the United States than in other countries. They conclude that “premium pricing [in the United States] exceeds what is needed to fund global R&D.” They further suggest that “lowering the magnitude of the US premium” would have saved $40 billion for US prescription drug purchasers in 2015. Essentially, the authors imply that the US price premium could be significantly reduced without affecting research and development investments or having other adverse effects. This is a strikingly b...
Source: Health Affairs Blog - June 2, 2017 Category: Health Management Authors: Henry Grabowski and Richard Manning Tags: Costs and Spending Drugs and Medical Innovation Featured Big Pharma drug innovation drug pricing Research and Development Source Type: blogs

What Experts in Law and Medicine Have to Say About the Cost of Drugs
By ANDY ORAM Pharmaceutical drug costs impinge heavily on consumers’ consciousness, often on a monthly basis, and have become such a stress on the public that they came up repeatedly among both major parties during the U.S. presidential campaign–and remain a bipartisan rallying cry. A good deal of the recent conference named Health Law Year in P/Review, at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, covered issues with a bearing on drug costs. It’s interesting to take the academic expertise from that conference–and combine it with a bit of commo...
Source: The Health Care Blog - February 2, 2017 Category: Consumer Health News Authors: John Irvine Tags: Uncategorized Andy Oram Drug Pricing Pharma Source Type: blogs

The American Drug Crisis -- It's Not What You Think
While we all love to hate the man with the most punchable face in America, Martin Shkreli, his despicable actions shed light on a situation all Americans will face at some time in our lives. The cost of prescription drugs is skyrocketing, and even with insurance picking up most of the tab, seniors are struggling to pay for life-saving new medicines. Unless something changes, prices will continue to go up. Photo Source In 2015, the FDA approved a slew of new drugs to treat everything from hepatitis C to MS. What those emotional commercials touting turnaround miracle drugs don't tell you is how much the miracle treatments ...
Source: Healthy Living - The Huffington Post - June 22, 2016 Category: Consumer Health News Source Type: news

Pages: 1  2